Investor Relations

Micreos is a privately owned company, operating and expanding around the world. We believe our products provide a meaningful benefit to people in all countries, irrespective of regional boundaries, just as the dangerous bacteria killed by our compounds are not restricted by borders.

Contact:

Mark Offerhaus (CEO)

Nicolaas Weeda (Corporate Secretary & General Counsel)

Mark Offerhaus, CEO of the Dutch biotechnology company Micreos, presents Staphefekt against MRSA in Amsterdam on Nov.6, 2014

NEWS

Micreos Raises 30 Million for Endolysin Technology Set to Replace Antibiotics

Press Release Dutch biotechnology company Micreos announced it has secured 30 million in fund ...

Micreos winner Finals Ideas from Europe 2018

Dutch biotech Micreos ‘sustainable alternative to antibiotics’ chosen as Europe& ...

Micreos one of 10 finalists at Ideas from Europe 2018

At the EU Conference in Tallinn, representing The Netherlands, MicreosAlternative to antibio ...

Antibiotic Alternative Micreos wins Most Impactful Innovation

The Hague, September 11, 2017 - In the presence of former UN-Secretary-General Kofi Annan an ...

Micreos granted a European (EFRO) subsidy to develop solutions to replace antibiotics in animals

View press release

More news

© 2010 - MICREOS